A New Hope for Metastatic Colorectal Cancer Patients: Trifluridine–Tipiracil and Bevacizumab

4 October, 2024

For patients with metastatic colorectal cancer, new hope is available through the combination of trifluridine–tipiracil (Lonsurf) and bevacizumab (Avastin), now accessible on the NHS. This therapy extends survival and offers an option after two rounds of treatment. In this blog, we’ll cover how it works, potential benefits, and important questions to discuss with your healthcare team.

Patients with metastatic colorectal cancer often encounter limited treatment options, particularly after two rounds of therapy. Fortunately, a promising new combination treatment—trifluridine–tipiracil (Lonsurf) with bevacizumab (Avastin)—is now available on the NHS. This therapy provides renewed hope for those who have previously undergone chemotherapy, including fluoropyrimidine, oxaliplatin, and irinotecan.

 How Does It Work?

The combination of trifluridine–tipiracil and bevacizumab has demonstrated an ability to extend both progression-free survival and overall life expectancy compared to alternatives like trifluridine–tipiracil alone or regorafenib. Bevacizumab inhibits the growth of blood vessels that supply tumours, thereby enhancing the effectiveness of trifluridine–tipiracil, which targets cancer cells by disrupting their DNA replication.

What Patients Should Consider

If you or a loved one is contemplating this treatment, it’s vital to engage in open discussions with your healthcare team. Consider asking the following questions:

– How does this treatment compare to other options?
– What side effects might I experience, and how likely are they?
– How will this treatment affect my daily life?
– What are the next steps if this treatment is ineffective, or if I choose not to pursue it?

Involving family members in these discussions can also help patients make informed decisions regarding their care. Empowering yourself with knowledge allows you to weigh the potential benefits and risks more effectively.

Personalised Care and Support

As with any treatment, what works for one individual may not be suitable for another. Healthcare professionals will provide tailored advice based on your medical history, current condition, and treatment objectives. It’s crucial to inquire about alternative treatments if you determine this option isn’t the best fit for you.

By staying informed and communicating transparently with your care team, you can make choices that align with your health priorities. This recent advancement brings renewed hope for improved outcomes, extending life and enhancing the quality of life for many patients.

For further details, read more about trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after two systemic treatments.

Read more: https://www.nice.org.uk/guidance/ta1008/chapter/1-Recommendation